Up-regulation of P-glycoprotein is involved in the increased paclitaxel resistance in human esophageal cancer radioresistant cells

Scandinavian Journal of Gastroenterology

Volumn 47, Issue 7, 2012, Pages 802-808

  Wang, Yan ^a   Chen, Qunfang ^b   Jin, Shu ^a   Deng, Weiping ^a   Li, Shengbao ^a   Tong, Qiang ^a   Chen, Yuezhou ^a  

^a WUHAN UNIVERSITY   (China)

^b Department of Pediatrics   (China)

Author keywords

esophageal cancer cells; P glycoprotein; radioresistance

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CISPLATIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GLYCOPROTEIN P; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; VERAPAMIL;

ARTICLE; CANCER CELL CULTURE; CHEMORADIOTHERAPY; CONTROLLED STUDY; DRUG CYTOTOXICITY; ESOPHAGUS CANCER; GAMMA IRRADIATION; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; IONIZING RADIATION; MDR1 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE FRACTIONATION; RADIOSENSITIVITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT FAILURE; UPREGULATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; COLONY-FORMING UNITS ASSAY; DRUG RESISTANCE; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION; HUMANS; NEOPLASMS, RADIATION-INDUCED; P-GLYCOPROTEIN; PACLITAXEL; RADIATION TOLERANCE; RNA, MESSENGER; UP-REGULATION; VERAPAMIL;

EID: 84862230354     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2012.683042     Document Type: Article

References (30)

1. Schuchert MJ, Luketich JD, Landreneau RJ. Management of esophageal cancer. Curr Probl Surg 2010;47:845-946.
2. Lin SH, Chang JY. Esophageal cancer: diagnosis and management. Chin J Cancer 2010;29:843-54.
3. Dahlberg WK, Azzam EI, Yu Y, Little JB. Response of human tumor cells of varying radiosensitivity and radiocurability to fractionated irradiation. Cancer Res 1999;59:5365-9. (Pubitemid 29504006)
4. Herskovic A, Martz K, Al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992;326:1593-8.
5. Takebayashi Y, Akiyama S, Natsugoe S, Hokita S, Niwa K, Kitazono M, et al. The expression of multidrug resistance protein in human gastrointestinal tract carcinomas. Cancer 1998;82:661-6. (Pubitemid 28090276)
6. Meyers MB, Rittmann-Grauer L, O'Brien JP, Safa AR. Characterization of monoclonal antibodies recognizing a Mr 180,000 P-glycoprotein: differential expression of the Mr 180,000 and Mr 170,000 P-glycoproteins in multidrug-resistant human tumor cells. Cancer Res 1989;49:3209-14. (Pubitemid 19162126)
7. Zhou SF. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 2008;38:802-32.
8. Seelig A. A general pattern for substrate recognition by P-glycoprotein. Eur J Biochem 1998;251:252-61. (Pubitemid 28081437)
9. McClean S, Whelan RD, Hosking LK, Hodges GM, Thompson FH, Meyers MB, et al. Characterization of the P-glycoprotein over-expressing drug resistance phenotype exhibited by Chinese hamster ovary cells following their in-vitro exposure to fractionated X-irradiation. Biochim Biophys Acta 1993;1177:117-26. (Pubitemid 23169565)
10. Uchiumi T, Kohno K, Tanimura H, Matsuo K, Sato S, Uchida Y, et al. Enhanced expression of the human multidrug resistance 1 gene in response to UV light irradiation. Cell Growth Differ 1993;4:147-57.
11. Chin KV, Tanaka S, Darlington G, Pastan I, Gottesman MM. Heat shock and arsenite increase expression of the multidrug resistance (MDR1) gene in human renal carcinoma cells. J Biol Chem 1990;265:221-6.
12. Fukuda K, Sakakura C, Miyagawa K, Kuriu Y, Kin S, Nakase Y, et al. Differential gene expression profiles of radioresistant oesophageal cancer cell lines established by continuous fractionated irradiation. Br J Cancer 2004;91:1543-50. (Pubitemid 39486360)
13. Tong Q, Zhang W, Jin S, Li S, Chen Z. The relationship between p27(kip1) expression and the change of radiosensitivity of esophageal carcinoma cells. Scand J Gastroenterol 2011;46:173-6.
14. Olivieri G, Bodycote J, Wolff S. Adaptive response of human lymphocytes to low concentrations of radioactive thymidine. Science 1984;223:594-7. (Pubitemid 14178754)
15. Matsuyama A, Inoue H, Shibuta K, Tanaka Y, Barnard GF, Sugimachi K, et al. Hepatoma-derived growth factor is associated with reduced sensitivity to irradiation in esophageal cancer. Cancer Res 2001;61:5714-17. (Pubitemid 32769083)
16. Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JJ, Al-Sarraf M, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999;281:1623-7. (Pubitemid 29211772)
17. Henness S, Davey MW, Harvie RM, Davey RA. Fractionated irradiation of H69 small-cell lung cancer cells causes stable radiation and drug resistance with increased MRP1, MRP2, and topoisomerase IIalpha expression. Int J Radiat Oncol Biol Phys 2002;54:895-902.
18. Osmak M, Miljanic S, Kapitanovic S. Low doses of gammarays can induce the expression of mdr gene. Mutat Res 1994;324:35-41.
19. Eisenmann S, Voigt W, Muller T, Dempke W. Sequential x-irradiation induced acquired resistance to oxaliplatin but increased sensitivity to Cisplatin in two human teratoma cell lines in vitro. Anticancer Res 2010;30:4471-6.
20. Seiwert TY, Salama JK, Vokes EE. The chemoradiation paradigm in head and neck cancer. Nat Clin Pract Oncol 2007;4:156-71. (Pubitemid 46358853)
21. Neuner G, Patel A, Suntharalingam M. Chemoradiotherapy for esophageal cancer. Gastrointest Cancer Res 2009;3:57-65.
22. Sakakura C, Miyagawa K, Fukuda KI, Nakashima S, Yoshikawa T, Kin S, et al. Frequent silencing of RUNX3 in esophageal squamous cell carcinomas is associated with radioresistance and poor prognosis. Oncogene 2007;26:5927-38.
23. Suchi K, Fujiwara H, Okamura S, Okamura H, Umehara S, Todo M, et al. Overexpression of Interleukin-6 suppresses cisplatin-induced cytotoxicity in esophageal squamous cell carcinoma cells. Anticancer Res 2011;31:67-75.
24. Wen J, Zheng B, Hu Y, Zhang X, Yang H, Li Y, et al. Comparative proteomic analysis of the esophageal squamous carcinoma cell line EC109 and its multi-drug resistant subline EC109/CDDP. Int J Oncol 2010;36:265-74.
25. Chavez JD, Hoopmann MR, Weisbrod CR, Takara K, Bruce JE. Quantitative proteomic and interaction network analysis of cisplatin resistance in HeLa cells. PLoS One 2011;6:e19892.
26. Kuwano M, Oda Y, Izumi H, Yang SJ, Uchiumi T, Iwamoto Y, et al. The role of nuclear Y-box binding protein 1 as a global marker in drug resistance. Mol Cancer Ther 2004;3:1485-92. (Pubitemid 39562593)
27. Kuwano M, Uchiumi T, Hayakawa H, Ono M, Wada M, Izumi H, et al. The basic and clinical implications of ABC transporters, Y-box-binding protein-1 (YB-1) and angiogenesis-related factors in human malignancies. Cancer Sci 2003;94:9-14. (Pubitemid 36575851)
28. Georges E, Sharom FJ, Ling V. Multidrug resistance and chemosensitization: therapeutic implications for cancer chemotherapy. Adv Pharmacol 1990;21:185-220.
29. Demeule M, Brossard M, Beliveau R. Cisplatin induces renal expression of P-glycoprotein and canalicular multispecific organic anion transporter. Am J Physiol 1999;277:F832-40. (Pubitemid 30046057)
30. Gu Y, Fan S, Liu B, Zheng G, Yu Y, Ouyang Y, et al. TCRP1 promotes radioresistance of oral squamous cell carcinoma cells via Akt signal pathway. Mol Cell Biochem 2011;357:107-13.